Mechanisms of Action (Proposed) Promotes nitric oxide synthesis and activates pathways involved in tissue repair and angiogenesis268
Its cardiovascular protective effects also benefit patients with heart conditions or those at risk for cardiovascular disease
Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days
[The question] is just whether or not increasing them synthetically is safe or not. There are several well-studied, FDA-approved peptides available today, such as insulin and GLP-1s like Ozempic and Wegovy, but thats just a sliver of the peptide pie
